PARPi treatment leads to the accumulation of dsDNA in the cytoplasm, which activates the cGAS-STING-TBK1-IRF3 innate immune pathway, enhances type I IFN response, increases the number of tumor-infiltrating lymphocytes and induces the immunogenic microenvironment (Fig. 3). This evidence concerns the gene CGAS and neoplasm.